What is HC Wainwright’s Forecast for ESPR FY2028 Earnings?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – HC Wainwright raised their FY2028 earnings estimates for shares of Esperion Therapeutics in a research report issued to clients and investors on Tuesday, January 13th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will post earnings of $1.07 per share for the year, up from their previous forecast of $0.90. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share.

Several other research firms have also recently issued reports on ESPR. Wall Street Zen upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. Piper Sandler initiated coverage on shares of Esperion Therapeutics in a report on Tuesday, November 25th. They issued an “overweight” rating and a $9.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Wednesday, October 8th. Finally, Citigroup reiterated a “market outperform” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Esperion Therapeutics has an average rating of “Moderate Buy” and an average target price of $7.20.

Esperion Therapeutics Stock Performance

ESPR opened at $3.13 on Wednesday. The stock has a market capitalization of $748.26 million, a PE ratio of -6.26, a P/E/G ratio of 6.60 and a beta of 1.04. Esperion Therapeutics has a one year low of $0.69 and a one year high of $4.18. The business’s 50 day moving average price is $3.57 and its 200 day moving average price is $2.66.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.07). The firm had revenue of $87.31 million for the quarter, compared to analyst estimates of $78.33 million.

Institutional Investors Weigh In On Esperion Therapeutics

Several large investors have recently added to or reduced their stakes in ESPR. DHJJ Financial Advisors Ltd. boosted its position in Esperion Therapeutics by 209.2% in the 3rd quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 6,380 shares during the period. North Star Investment Management Corp. acquired a new stake in shares of Esperion Therapeutics in the second quarter valued at $25,000. Sivia Capital Partners LLC purchased a new position in Esperion Therapeutics in the second quarter valued at $25,000. Vanguard Personalized Indexing Management LLC acquired a new position in Esperion Therapeutics during the 3rd quarter worth $29,000. Finally, R Squared Ltd purchased a new stake in Esperion Therapeutics during the 3rd quarter worth about $33,000. 47.39% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Benjamin Halladay sold 7,337 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total value of $26,926.79. Following the completion of the transaction, the chief financial officer owned 467,525 shares of the company’s stock, valued at approximately $1,715,816.75. This trade represents a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.70% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.